Microfluidics assembly of inhalable liposomal ciprofloxacin characterised by an innovative in vitro pulmonary model

Zhang, Ye; Wong, Chun Y; Gholizadeh, Hanieh; Aluigi, Annalisa; Tiboni, Mattia; Casettari, Luca; Young, Paul M.; Traini, Daniela; Li, Ming; Cheng, Shaokoon; Ong, Hui Xin

doi:10.1016/j.ijpharm.2023.122667

Cited by 12 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, research conducted by Zhang's team prepared CFX liposomes and their study showed −10 mV and 105 nm for surface charge and particle size, respectively. Slower in vitro drug release was observed up to 24 h (95%) [58]. As with previous clinical trials, administering liposomal CFX via inhalation resulted in a decrease in bacterial burden.…”

Section: Liposomessupporting

confidence: 76%

“…In addition, a study performed by Tureli et al fabricated CFX-incorporated PLGA nanoparticles and examined their antibacterial efficacy against P. aeruginosa in lung infections associated with CF. In their research, the cytotoxicity assessments conducted on Calu-3 cells and CF bronchial epithelial cells (CFBE41o-) demonstrated that the PLGA nanoparticles encapsulated with the complex exhibited no toxicity Furthermore, Zhang et al [58] recently evaluated the antibiofilm effectiveness of two inhalable liposomal CFX fabrications with varied vesicle sizes fabricated by applying a 3D-printed microfluidic chip. Their findings indicated that both liposomal-contained CFX preparations and the free CFX solution exhibited similar properties in terms of aerosolization and effectiveness in eradicating biofilms.…”

Section: Cfx Inhalable Formulations For Lrtis Management In Preclinic...mentioning

confidence: 99%

“…Notably, the CFX liposomal formulation with a smaller vesicle size exhibited a considerably slower release of the drug when subjected to the dialysis bag approach in comparison with the free CFX solution. Surprisingly, CFX liposomal fabrications effectively controlled drug release when tested in the alveolar epithelial H441 cell model, and they exhibited unique drug transport behaviors in H441 cell lines when contrasted with the free CFX solution (Figure 5), indicating the potential of inhaled liposomal CFX as a promising remedial strategy for respiratory infections [58].…”

Section: Cfx Inhalable Formulations For Lrtis Management In Preclinic...mentioning

confidence: 99%

See 2 more Smart Citations

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Panthi,

Fairfull-Smith,

Islam

2024

Pharmaceutics

View full text Add to dashboard Cite

Inhaled ciprofloxacin (CFX) has been investigated as a treatment for lower respiratory tract infections (LRTIs) associated with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and bronchiectasis. The challenges in CFX effectiveness for LRTI treatment include poor aqueous solubility and therapy resistance. CFX dry powder for inhalation (DPI) formulations were well-tolerated, showing a remarkable decline in overall bacterial burden compared to a placebo in bronchiectasis patients. Recent research using an inhalable powder combining Pseudomonas phage PEV20 with CFX exhibited a substantial reduction in bacterial density in mouse lungs infected with clinical P. aeruginosa strains and reduced inflammation. Currently, studies suggest that elevated biosynthesis of fatty acids could serve as a potential biomarker for detecting CFX resistance in LRTIs. Furthermore, inhaled CFX has successfully addressed various challenges associated with traditional CFX, including the incapacity to eliminate the pathogen, the recurrence of colonization, and the development of resistance. However, further exploration is needed to address three key unresolved issues: identifying the right patient group, determining the optimal treatment duration, and accurately assessing the risk of antibiotic resistance, with additional multicenter randomized controlled trials suggested to tackle these challenges. Importantly, future investigations will focus on the effectiveness of CFX DPI in bronchiectasis and COPD, aiming to differentiate prognoses between these two conditions. This review underscores the importance of CFX inhalable formulations against LRTIs in preclinical and clinical sectors, their challenges, recent advancements, and future perspectives.

show abstract

Section: Liposomessupporting

confidence: 76%

Section: Cfx Inhalable Formulations For Lrtis Management In Preclinic...mentioning

confidence: 99%

Section: Cfx Inhalable Formulations For Lrtis Management In Preclinic...mentioning

confidence: 99%

See 1 more Smart Citation

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Panthi,

Fairfull-Smith,

Islam

2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The airway epithelium comprises various cell types that demonstrate compromised morphology in conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), asthma, and lung cancer. 18 In COPD, fine bronchi are obstructed and disappear, leading to emphysema. Basal cell hyperplasia is considered to be the initial lesion in COPD.…”

Section: Anatomy and Biological Barriers Of The Lungmentioning

confidence: 99%

Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review

Feng,

Shi,

Zhang

et al. 2024

IJN

Self Cite

View full text Add to dashboard Cite

Lungs experience frequent interactions with the external environment and have an abundant supply of blood; therefore, they are susceptible to invasion by pathogenic microorganisms and tumor cells. However, the limited pharmacokinetics of conventional drugs in the lungs poses a clinical challenge. The emergence of different nano-formulations has been facilitated by advancements in nanotechnology. Inhaled nanomedicines exhibit better targeting and prolonged therapeutic effects. Although nano-formulations have great potential, they still present several unknown risks. Herein, we review the (1) physiological anatomy of the lungs and their biological barriers, (2) pharmacokinetics and toxicology of nanomaterial formulations in the lungs; (3) current nanomaterials that can be applied to the respiratory system and related design strategies, and (4) current applications of inhaled nanomaterials in treating respiratory disorders, vaccine design, and imaging detection based on the characteristics of different nanomaterials. Finally, (5) we analyze and summarize the challenges and prospects of nanomaterials for respiratory disease applications. We believe that nanomaterials, particularly inhaled nano-formulations, have excellent prospects for application in respiratory diseases. However, we emphasize that the simultaneous toxic side effects of biological nanomaterials must be considered during the application of these emerging medicines. This study aims to offer comprehensive guidelines and valuable insights for conducting research on nanomaterials in the domain of the respiratory system.

show abstract

“…[171] Zhang et al reported a novel microfluidic platform for the realtime in situ electrochemical monitoring of Pseudomonas aeruginosa biofilms and their antibiotic sensitivity (Figure 13d). [172] They established a co-culture model of P. aeruginosa biofilms and human epithelial cells to simulate the physiological reality of the environment and studied lung infections and antibiotic treatment effects. Direct deposition of drugs on biofilms is threefold more effective than indirect drug exposure.…”

Section: Drug Resistance Studymentioning

confidence: 99%

Microfluidic Platforms for Real‐Time In Situ Monitoring of Biomarkers for Cellular Processes

Lou,

Yang,

Hou

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Cellular processes are mechanisms carried out at the cellular level (within or among more than one cell interactions) that are aimed at guaranteeing the stability of the organism they comprise. The investigation of cellular processes is key to understanding cell fate, understanding pathogenic mechanisms, and developing new therapeutic technologies. Microfluidic platforms are thought to be the most powerful tools among all methodologies for investigating cellular processes because they can integrate almost all types of the existing intracellular and extracellular biomarker‐sensing methods and observation approaches for cell behavior, combined with precisely controlled cell culture, manipulation, stimulation, and analysis. Most importantly, microfluidic platforms can realize real‐time in situ detection of secreted proteins, exosomes, and other biomarkers produced during cell physiological processes (adhesion, differentiation, migration, apoptosis, and cell‐to‐cell communication), thereby providing the possibility to draw the whole picture for a cellular process. In addition, these can be used to study the process of cell or tissue response to changes in the microenvironment (drugs, physical signals, or types and quantities of surrounding cells). Owing to their advantages of high throughput, low sample consumption, and precise cell control, microfluidic platforms with real‐time in situ monitoring characteristics are widely being used in cell analysis (cellular heterogeneity analysis, cell sorting, and cellular marker detection), disease diagnosis, pharmaceutical research, and biological production. This review focuses on the basic concepts, recent progress, and application prospects of microfluidic platforms for real‐time in situ monitoring of biomarkers in cellular processes.This article is protected by copyright. All rights reserved

show abstract

Microfluidics assembly of inhalable liposomal ciprofloxacin characterised by an innovative in vitro pulmonary model

Cited by 12 publications

References 38 publications

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review

Microfluidic Platforms for Real‐Time In Situ Monitoring of Biomarkers for Cellular Processes

Contact Info

Product

Resources

About